Zobrazeno 1 - 10
of 29
pro vyhledávání: '"S, Gally"'
Autor:
J Dupin, K Thokagevistk, L Emonnot, S Micon, K Benyounes, D Havet, A Civet, D Pau, C Le Dissez, S Gally, C Esnault
Publikováno v:
Value in Health. 25:S456-S457
Autor:
Vlatka Smoljanovic, S Gally, Pascale Tomasini, Adam Gondos, Stefan Hammerschmidt, Gracy Crane, Nasreen Khan, Nuria Lara
Publikováno v:
Lung Cancer. 149:144-153
Objectives Quantify the burden of central nervous system (CNS) metastases on health-related quality of life (HRQoL) and healthcare resource use (HRU) in patients with advanced non-small-cell lung cancer (NSCLC) from a prospective European study in cl
Autor:
F. Martin, G. De Faverges, Didier Debieuvre, P.-A. Hauss, Michel Grivaux, F. Goupil, Philippe Brun, L. Moreau, M. Coudert, C. Locher, S. Gally, Charles Dayen, B. Asselain, D. Coëtmeur, B. Ben Hadj Yahia
Publikováno v:
Revue des Maladies Respiratoires. 36:649-663
Resume Introduction Le benefice des inhibiteurs de la tyrosine kinase specifiques de l’EGFR, chez des patients sans mutation de l’EGFR, est controverse. Methodes La survie de patients traites par erlotinib en 2e ou 3e ligne pour un cancer bronchi
Autor:
S Gally, Eric Houvenagel, Laurent Marguerie, René-Marc Flipo, X. Deprez, Nicolas Lecuyer, Jean-Paul Eschard, Isabelle Idier, Marie-Hélène Guyot, Jean Darloy, Guy Baudens, D Pau, Jean-Hugues Salmon, Vincent Goëb, N. Segaud
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 1, Pp 61-75 (2019)
Rheumatology and Therapy
Rheumatology and Therapy
Introduction The main objective of this work was to assess the maintenance of effectiveness of subcutaneous tocilizumab 6 months after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis (RA) in a real-world s
Publikováno v:
Annals of Oncology. 31:S1038
Autor:
J.H. Salmon, C. Chopin, Guy Baudens, Marie-Hélène Guyot, Vincent Goëb, S Gally, Isabelle Idier, R.M. Flipo, J. Darloy, Laurent Marguerie, N. Segaud
Publikováno v:
Rheumatoid arthritis – biological DMARDs.
Background It has been proven, in a pivotal RCT, that SC tocilizumab (TCZ) was non-inferior to IV TCZ.1 However the switch from IV to SC TCZ has not been evaluated to date in a large real-world study. Objectives The main objective was to assess the m
Autor:
D, Debieuvre, L, Moreau, M, Coudert, C, Locher, B, Asselain, D, Coëtmeur, C, Dayen, F, Goupil, F, Martin, P, Brun, G, De Faverges, P-A, Hauss, S, Gally, B, Ben Hadj Yahia, M, Grivaux
Publikováno v:
Revue des maladies respiratoires. 36(6)
The benefit of tyrosine kinase inhibitors for patients with an EGFR wild-type non-small cell lung cancer (NSCLC) remains controversial.The survival of patients with an EGFR wild-type NSCLC who received second- or third-line erlotinib treatment was as
Autor:
R.M. Flipo, G. Baudens, Eric Houvenagel, N. Segaud, Vincent Goëb, D Pau, X. Deprez, Jean-Hugues Salmon, S Gally, J Eschard, C. Chopin, J. Darloy, I. Idier
Publikováno v:
Value in Health. 20:A526-A527
Autor:
A. Stephan, C. Lebbé, M. Mouri, S. Gally, Thierry Lesimple, Clara Allayous, Stéphane Dalle, C. Dutriaux, M.-T. Leccia, L. Mortier, J.-P. Lacour, Vincent Descamps, P.-E. Stoebner, F. Aubin, Jean-Philippe Arnault, Sophie Dalac, E. Maubec, A. Dupuy, Marie Beylot-Barry, Bernard Guillot, A. Kowal, B. Dréno, Raphaël Porcher, Isabelle Borget, P. Saiag, J. De Quatrebarbes
Publikováno v:
Revue d'Épidémiologie et de Santé Publique. 64:S289-S290
Objectifs Cette analyse sur base de donnees visait a decrire en vie reelle l’efficacite, la tolerance et l’utilisation du vemurafenib en monotherapie chez des patients atteints d’un melanome metastatique ou inoperable. Methode Les donnees ont e
Publikováno v:
Value in Health. 20:A653